History of Heart Attacks
There is an increased risk of having another
heart-attack in such patients. The heart-attack may be fatal during the first week of using this medicine. Avoid the use of Meftal P in patients with a recent heart attack unless the benefits are more than the risk. If used, monitor the patients for signs of heart attack.
Previously have had Heart Surgery
The patients may have an increased incidence of heart attack and
stroke while using this medicine. In such patients,
NSAIDs should not be used.
Women in their Third Trimester of Pregnancy
Pregnant women are at increased risk while using this medicine. Such patients may have an increased risk of a life-threatening problem (a rare heart disease) in the unborn baby. Avoid use of this medicine in the third trimester of
pregnancy.
Serious Skin Reactions
Patients with severe skin reactions are at increased risk while using this medicine. Such patients may develop an increased risk of severe allergic reactions. Discontinue the use of this medicine at the first appearance of a skin rash or any other sign of
allergy.
Liver Disorders
Patients with liver disorders are at increased risk while using this medicine. Such patients may have an increased risk of increase in levels of certain organic chemicals that can result in liver related issues, including liver injury or liver damage. Discontinue this medicine if you face any liver related issues.
Anemia
Patients with long-term treatment of this medicine are at an increased risk of development of
anemia. Proper monitoring of the hemoglobin levels in the blood is required for these patients.
High Blood Pressure
Patients who already have high blood pressure are at increased risk while using this medicine. These patients may have worsening of existing high blood pressure and an increased risk of heart related issues. Monitor your blood pressure level when you start taking this medicine and continue monitoring while you are using this medicine.
Severe Heart Disease
Patients with severe heart diseases are at an increased risk when using this medicine. Such patients have an increased risk of severe heart diseases (blood clot formation, heart attack,
stroke, and fluid retention in the body), which are possibly fatal. Use the lowest effective dose for a shorter duration in such patients.
Elderly Patients
Elderly patients are at increased risk while using this medicine. Such patients may have an increased risk of
bleeding in the stomach or intestines, and ruptured bowel. Use this medicine only when the potential benefit outweighs the risk.
Stomach Ulcer
Patients with a previous history of stomach
ulcers are at an increased risk when using this medicine. Such patients may have an increased risk of
bleeding in the stomach or intestines. Use the lowest effective dose for a shorter duration in such patients.
Heart Failure and Fluid Retention
Patients treated with
NSAIDs such as Meftal P may experience the condition of fluid build up and water retention in body tissues. Use of this medicine may reduce the effect of other medicines used to treat heart diseases (e.g.,
diuretics, ACE inhibitors, or angiotensin receptor blockers). Avoid the use of Meftal P in patients with severe heart failure unless the benefits are more than the risk of worsening of heart failure. If Meftal P is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
History of Aspirin-Related Asthma
Patients with history of aspirin-related
asthma may suffer from an asthmatic attack because of intolerance to
NSAIDs. This medicine should not be used in patients who are sensitive to aspirin. When Meftal P is used in asthma patients, monitor the patient for signs and symptoms of an asthma attack.
Kidney Damage
The long-term intake of
NSAIDs may result in kidney failure or injury. If such an event happens, the NSAID therapy should be discontinued.
Increase in Potassium Levels in the Blood
An increase in
potassium levels, including
hyperkalemia, have been reported with use of
NSAIDs. This may lead to certain illnesses called as, hyporeninemic-hypoaldosteronism state.
Lupus and Connective Tissue Disorders
Patients with
lupus and connective tissue disorders are at an increased risk when using this medicine. There may be an increased risk of inflammation of brain and backbone membrane caused by an infection in patients with such disorders.